ライフサイエンスコーパス: ever smoker

1 between ages 20 and 64 years (52% male; 63% ever-smoker).

2 1 vs 2), and smoking status (never-smoker vs ever-smoker).

3 92.2%] who currently or formerly smoked (ie, ever-smokers).

4 t the time of disease onset or at diagnosis (ever-smokers).

5 ded association with hip fracture risk among ever smokers.

6 s with pancreatic cancers in this study were ever smokers.

7 the rs4678408 association was only found in ever smokers.

8 of incident AAMD in never smokers and 60% in ever smokers.

9 and better lung function, particularly among ever smokers.

10 re aged >=60 years, and 176 053 (54.0%) were ever smokers.

11 nted with mesh longer, and more likely to be ever smokers.

12 reen leafy vegetables and fish, in never and ever smokers.

13 can ancestry and 395 CpGs unique to never or ever smokers.

14 These associations seem to be stronger in ever smokers.

15 ssociations separately for never smokers and ever smokers.

16 was inversely associated with lung cancer in ever smokers.

17 G, OR = 1.46, 95% CI: 1.12, 1.90) but not in ever smokers.

18 %), while 43% of patients were classified as ever smokers.

19 subsequently categorized as never smokers or ever smokers.

20 rs was 10.3% for never smokers and 21.3% for ever smokers.

21 P were more likely to have higher BMI and be ever-smokers.

22 95 (35%) were men, and 73 of 268 (27%) were ever-smokers.

23 nger CHD protection in never-smokers than in ever-smokers.

24 and all-cause mortality were only present in ever-smokers.

25 C, especially in the ipsilateral lung, among ever-smokers.

26 n's disease was 0.59 (95% CI, 0.54-0.63) for ever smokers, 0.80 (95% CI, 0.69-0.93) for past smokers,

27 was greater than in never-smokers (13%) and ever-smokers (12%).

28 Study in our study: 2199 never-smokers, 5435 ever-smokers, 158 with asthma, 320 with COPD, 68 with as

29 The YLG was 23 for all ever-smokers, 19 for the USPSTF 2013 criteria, and 21 fo

30 ever-smokers (2.84%; 95% CI, 1.50%-4.18%) as ever-smokers (2.72%; 95% CI, 2.24%-3.20%), which led to

31 never-smokers (14.50; 95% CI, 8.73-22.65) vs ever-smokers (3.50; 95% CI, 2.95-4.12).

32 0) baseline pack-years, including 2371 heavy ever smokers (406 [17%] former and 1965 [83%] current).

33 hout VRF and 106 MS with one or more VRF (80 ever-smokers, 43 hypertensives, 25 dyslipidaemics and 10

34 he Norwegian GenKOLS study of 2003-2005, 947 ever-smokers (49% with COPD) aged 40-85 years performed

35 ed selection screening of the same number of ever-smokers (9.0 million) at highest 5-year lung cancer

36 f those who developed pancreatic cancer were ever smokers (92% vs 69%, respectively), but this did no

37 In ever smokers, a high-risk-inducing profile was independe

38 Among ever smokers, a higher number of pack-years was associat

39 ith newly diagnosed SCCHN were matched to 50 ever smokers according to sex, age, tumor site, overall

40 adjusted OR, 1.32; 95% CI, 1.02-1.70) and in ever smokers (adjusted OR, 1.75; 95% CI, 1.37-2.22) than

41 brated and validated mortality model in U.S. ever-smokers aged 40 to 84 years and selecting 8.3 milli

42 Eligible patients were ever-smokers aged 40-79 years without a previously recor

43 e eligible population for LCS was 27 280 920 ever-smokers aged 50 to 80 years (13 387 552 female [49.

44 del calibrated and discriminated well for US ever-smokers aged 50 to 80 years (NHIS 1997-2001: estima

45 Models were applied to US ever-smokers aged 50 to 80 years to estimate outcomes of

46 ince cessation), and USPSTF 2021 guidelines (ever-smokers aged 50 to 80 years with 20 pack-years and

47 Among a cohort of US ever-smokers aged 50 to 80 years, application of a risk-

48 Exposures included ever-smokers aged 50 to 80 years, US Preventive Services

49 Participants included ever-smokers aged 50 to 80 years.

50 ed tomography (CT) lung cancer screening for ever-smokers aged 55 to 80 years who have smoked at leas

51 ervices Task Force (USPSTF) 2013 guidelines (ever-smokers aged 55 to 80 years with >=30 pack-years an

52 -L1 mRNA expression only in never-and not in ever-smoker AMs.

53 l discrimination in the subgroup analysis of ever smokers and in adjusted models.

54 ble fundamental differences in SCCHN between ever smokers and never smokers may exist, and further mo

55 antibody response was associated with CHD in ever smokers and never smokers.

56 ngzhou Biobank Cohort Study, after excluding ever smokers and those with poor health, 19,405 Chinese

57 ents and Main Results: Overall, 115 LFs from ever-smokers and Global Initiative for Chronic Obstructi

58 Ci/L) with smoking status (never smokers and ever smokers) and radon level with PM2.5 level (above or

59 al disease was higher in older age, females, ever-smokers, and hypertensive participants.

60 ng-concordant pairs (r = 0.483, p < 0.01 for ever-smokers, and r = 0.280, p < 0.05 for never-smokers)

61 d Main Results: WTC-LI cases were more often ever-smokers, arrived in the morning (9/11), and had Met

62 ified models, there were FEV1 deficits among ever-smokers associated with infant lower respiratory in

63 In ever-smokers, associations were tested between each airw

64 iple sclerosis severity score was greater in ever-smokers, by 0.68 (95% confidence interval: 0.36-1.0

65 In ever smokers, changes in smoking cessation, and cumulati

66 No associations were found in ever-smokers (clinical AL by smoking interaction: P <0.0

67 roteomics of 4,383 participants in an older, ever-smoker cohort (COPDGene [Genetic Epidemiology of Ch

68 ary progression was 3.6 (95% CI 1.3-9.9) for ever smokers compared with never smokers.

69 of multiple sclerosis was 1.3 (1.0-1.7) for ever smokers compared with never smokers.

70 Status Scale score milestones of 4 and 6 in ever-smokers compared to never-smokers was 1.34 (95% con

71 6 794 [69%] non-Hispanic white; 15 181 [63%] ever smokers), complete follow-up was available for 11 0

72 models to predict the risk of lung cancer in ever-smokers, demonstrating a novel approach that could

73 and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunos

74 increased ESCC risk, particularly for males, ever-smokers, ever-drinkers, and those with age > 60, or

75 Compared with never-smokers, ever smokers experienced significantly shorter DFS (3-ye

76 Among ever-smokers, factors associated with the likelihood of

77 2 groups combined into a single category of ever smokers for analysis.

78 ere stronger for squamous cell carcinoma and ever smokers for the "fruits and vegetables" pattern, an

79 Although risk-based selection of ever-smokers for screening could prevent more lung cance

80 However, selecting ever-smokers for screening using individualized lung can

81 participants had lower hazard of death among ever-smokers (for overweight, adjusted hazard ratio (aHR

82 etic aging markers tended to be stronger in "ever-smokers" (former and current smokers) compared to "

83 Starting with 94,050 ever-smokers from 43 studies, we extracted the heavy smo

84 rials and Methods In a secondary analysis of ever-smokers from the prospective, observational, multic

85 in the absence of CT screening using data on ever-smokers from the Prostate, Lung, Colorectal, and Ov

86 lome associated with respiratory outcomes in ever-smokers from the SPIROMICS cohort.

87 ohorts (pooled) and were restricted to heavy ever smokers (>=20 pack-years).

88 Compared with never smokers, ever smokers had a 1.11-fold (95% confidence interval (C

89 HR = 1.03, 95% CI: 0.89, 1.18), while female ever smokers had a 20% higher risk (HR = 1.20, 95% CI: 1

90 red with never smokers of the same sex, male ever smokers had a 39% higher risk (hazard ratio (HR) =

91 ariable models, compared with never smokers, ever smokers had a significantly increased risk of cance

92 Ever smokers had increased risks of lung cancer, coronar

93 [n = 3]) were older, were more likely to be ever smokers, had shorter peripheral blood mononuclear c

94 ted with significantly lower mortality among ever smokers (HR, 0.96; 95% CI, 0.93-0.99; P = .003).

95 ; 95% CI, 1.01 to 2.57; P trend = .002) than ever-smokers (HR, 1.36; 95% CI, 0.86 to 2.15; P trend =

96 mokers who had stopped by choice (only 3% of ever-smokers in 1991, but 9% in 2006) had little smoking

97 had PLCOm2012 of less than 1.51% at 6 years, ever-smokers in the Prostate Lung Colorectal and Ovarian

98 Measurements and Main Results: Among ever-smokers in the test set, a machine learning model w

99 reservation to create a synthetic version of ever-smokers in the UK Biobank before building prognosti

100 he association with NBN E185Q was limited to ever smokers (interaction P = 0.002) and was strongest f

101 Elevated odds of GD were also observed in ever smokers living in counties with a higher (>=2 pCi/L

102 us mutations in the carcinomas obtained from ever smokers (mean, 53.1 mutations per tumor; SD, 27.9)

103 Among ever smokers (median pack-years: 20, males; 12, females)

104 activity index, smoking (never compared with ever smokers), multivitamin use, season of BMD measureme

105 In ever-smokers (n = 9363), men had greater segmental airwa

106 on-based cohorts examining all participants, ever smokers, never smokers, asthma-free participants, a

107 ratified genome-wide association analysis in ever smokers, never smokers, individuals with diabetes,

108 nd UC combined), comparing data for never vs ever smokers, never vs current smokers, and never vs for

109 Compared with ever-smokers, never-smokers were older (median age [IQR]

110 By contrast, among ever smokers, obesity was not prognostic, and overweight

111 This association was limited to ever smokers (odds ratio = 2.5, 95% confidence interval:

112 Among ever smokers of cigarettes (100 cigarettes), ever e-ciga

113 ge, and lifetime pack-years of smoking among ever smokers or lifetime intensity-years of passive smok

114 significantly associated with CHD in either ever smokers or never smokers.

115 lybdenum association was only observed among ever smokers (OR = 0.31 [95% CI, 0.17-0.58]; P = .003 fo

116 ers (OR = 0.64, p < 0.001) disappeared among ever smokers (OR = 1.00, p = 0.99).

117 45 years (ORadj = 4.79; 95% CI = 1.87-12.3), ever-smokers (ORadj = 5.55; 95% CI = 1.85-16.6), alcohol

118 We recruited 224 ever smokers over 40 years of age and with greater than

119 ever smokers P(1df interaction)<2.65x10(-4); ever smokers P(1df interaction)<1.71x10(-5)); rs3130553,

120 and never smokers than BMI >= 23 kg/m(2) and ever smokers (P's(heterogeneity) = 0.003 and 0.021, resp

121 fruit intake for men was more evident among ever smokers (P(trend) = 0.001) than never smokers (P(tr

122 bese participants (P for trend = 0.006), and ever-smokers (P for trend = 0.0005).

123 ers (P=1.3x10(-16)) in comparison with 5% in ever-smokers (P=2.5x10(-4)), translating to a 60% loss o

124 Among ever smokers, participants in the highest quintile of vi

125 All genetic effects were evident only in "ever smokers" (persons who had smoked >or=100 cigarettes

126 atic changes after simultaneous exclusion of ever smokers, persons with a history of cancer or cardio

127 bank prospective cohort and 26,616 high-risk ever-smokers recruited between 2002 and 2004 to the cont

128 model development, we used data from 216,714 ever-smokers recruited between 2006 and 2010 to the UK B

129 In ever-smokers, relative to the first quintile, HRs for qu

130 from any cause was found in male and female ever-smokers, respectively.

131 ators of 1L platinum chemotherapy, for which ever-smokers showed significantly shorter OS compared wi

132 e reductions in risk were more pronounced in ever smokers, suggesting a gene-environment interaction.

133 rates than men in Taiwan for both never and ever smokers, suggesting the possibility of differential

134 vel on pulmonary function was stronger among ever smokers than never smokers, suggesting an interacti

135 7 sites showed higher methylation changes in ever-smokers than in nonsmokers.

136 15q25.1 meeting genome-wide significance in ever smokers that includes AGPHD1, IREB2, and CHRNA5/CHR

137 .24, 0.62; P < 0.0001); after restriction to ever smokers, the difference in slopes was much smaller

138 For lung cancer in ever smokers, the inverse association was statistically

139 effect modification by smoking: among women ever smokers, there was a positive, progressive dose-res

140 was 54 years, 52% were female, and 38% were ever-smokers; these characteristics were not significant

141 ged 40 to 84 years and selecting 8.3 million ever-smokers to match the number selected by the USPSTF

142 had never smoked cigarettes, the risk among ever smokers was not increased (odds ratio (OR) = 1.05,

143 e sex-specific ageing-related increase among ever smokers was strongly related to cumulative tobacco

144 ema progression quantified by CT scans among ever-smokers was highly variable; clinical factors and b

145 Among ever smokers, we found SNPs in CTSH (rs34577742 C > T, O

146 Lung sections from 40 patients with COPD and ever-smokers were used for LF proteomic and transcriptom

147 ecline in FEV1 and FEV1%VC, especially among ever smokers, where we found an excess change in FEV1 of

148 are significantly associated with CHD among ever smokers, whereas Prevotella nigrescens (OR=1.7; 95%

149 , 46.8% for GrimAA, and 10.3% for PhenoAA in ever-smokers, whereas no significant mediation was obser

150 idence was 2.40% (95% CI, 2.31%-2.49%) among ever-smokers, which was 7 times higher than never-smoker

151 with never-smoking Gly-16 homozygotes, those ever-smokers who are Arg-16 homozygotes had a significan

152 ds ratios were 5.9 (95% CI, 2.7 to 12.8) for ever-smokers who did not receive PMRT and 18.9 (95% CI,

153 creening in the U.S. population by including ever-smokers who have both high lung cancer risk and lon

154 After adjustment for baseline covariates, ever-smokers who initiated 1L pembrolizumab had signific

155 eive PMRT and 18.9 (95% CI, 7.9 to 45.4) for ever-smokers who received PMRT.

156 There were 5308 ever smokers with a median 17.2 (interquartile range, 7-

157 In two different cohorts of ever smokers with COPD or NSCLC, and ever and never smok

158 of less than 25 kg/m (OR: 1.6, CI: 0.8-3.5), ever smokers with never smokers (OR: 1.4, 95% CI: 0.7-2.

159 sized that the primary determinant of GCH in ever smokers with or without airflow obstruction is acti

160 ered significantly between never smokers and ever smokers with SCCHN.

161 We examined "ever" smokers with COPD (n = 13) lung tissue sections co

162 We found that "ever" smokers with COPD had higher ANO1 expression.

163 screening from ages 55 through 80 years for ever-smokers with a smoking history of at least 30 pack-

164 Reduced serum amino acid concentrations in ever-smokers with and without COPD are associated with a

165 magnetic resonance spectroscopy in 157 white ever-smokers with and without COPD.

166 Of the 141 ever-smokers with baseline and repeat CT scans, the mean

167 /FVC 0.7), 264 control participants, and 170 ever-smokers with chronic obstructive pulmonary disease

168 Conclusion In ever-smokers with chronic obstructive pulmonary disease,

169 tion with exercise capacity and mortality in ever-smokers with COPD enrolled in the COPDGene Study.Me

170 Conclusion In ever-smokers with emphysema, emphysema progression at CT

171 Overall, 3,042 (71.7%) were ever-smokers with mean tobacco exposure of 33 pack-years

172 Methods: Ever-smokers with QIAs, outcomes, and pulmonary vascular

173 guidelines, it preferentially selects older ever-smokers with shorter life expectancies due to comor

174 Participants included 445 never-smokers, 381 ever-smokers without airflow obstruction, 224 with Globa

175 In never- and ever-smokers without airflow obstruction, aging is assoc

176 y into six subgroups: healthy never-smokers, ever-smokers without asthma and COPD, those with asthma

177 signatures from lymphoid follicles (LFs) in ever-smokers without COPD and patients with COPD with va

178 In 26 patients with COPD, 24 ever-smokers without COPD, 32 nonsmokers who underwent a

179 Among 580 never- and ever-smokers without obstruction or respiratory impairme

180 dations, the models estimated 9.0 million US ever-smokers would qualify for lung cancer screening and

181 T lung screening, assuming screening for all ever-smokers, yield the percent changes in lung cancer d